While it may be the case that a takeover would see 'someone else' reap the rewards of taking this treatment on, it is worth remembering that there will probably be an opportunity to buy shares in the takeover company.
I'm still intrigued by polygon's position. Have they simply averaged down are they protecting their position with their 25% or are they going to orchestrate a takeover?
RE: Meanwhile on the other chat group...09 May 2022 16:49
To be fair the actual inside track was that p3 would be a success.
The result was as much a surprise to the insiders as it was to everyone even after allowing for the usual stats that, due to the nature of p3 trials, they are much more likely to fail than p2.
That particular stat was largely ignored on here and other forums and the only real negative talk was of market share being affected by other treatments, and of course vaccines making treatments redundant. Neither held any water but still get trotted out by the uninformed.